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Abstract
Background: As highly effective hepatitis C virus (HCV) therapies emerge, data are needed to inform the development of
interventions to improve HCV treatment rates. We used simulation modeling to estimate the impact of loss to follow-up on
HCV treatment outcomes and to identify intervention strategies likely to provide good value for the resources invested in
them.
Methods: We used a Monte Carlo state-transition model to simulate a hypothetical cohort of chronically HCV-infected
individuals recently screened positive for serum HCV antibody. We simulated four hypothetical intervention strategies
(linkage to care; treatment initiation; integrated case management; peer navigator) to improve HCV treatment rates, varying
efficacies and costs, and identified strategies that would most likely result in the best value for the resources required for
implementation.
Main measures: Sustained virologic responses (SVRs), life expectancy, quality-adjusted life expectancy (QALE), costs from
health system and program implementation perspectives, and incremental cost-effectiveness ratios (ICERs).
Results: We estimate that imperfect follow-up reduces the real-world effectiveness of HCV therapies by approximately 75%.
In the base case, a modestly effective hypothetical peer navigator program maximized the number of SVRs and QALE, with
an ICER compared to the next best intervention of $48,700/quality-adjusted life year. Hypothetical interventions that
simultaneously addressed multiple points along the cascade provided better outcomes and more value for money than less
costly interventions targeting single steps. The 5-year program cost of the hypothetical peer navigator intervention was
$14.5 million per 10,000 newly diagnosed individuals.
Conclusions: We estimate that imperfect follow-up during the HCV cascade of care greatly reduces the real-world
effectiveness of HCV therapy. Our mathematical model shows that modestly effective interventions to improve follow-up
would likely be cost-effective. Priority should be given to developing and evaluating interventions addressing multiple
points along the cascade rather than options focusing solely on single points.
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Introduction
Recognizing that hepatitis C virus (HCV) is a highly prevalent
but under-diagnosed infection, the U.S. Centers for Disease
Control and Prevention (CDC) recently updated guidelines to
recommend routine, one-time screening for HCV infection among
all individuals born between 1945 and 1965 [1]. As these
guidelines are implemented, the number of people with identified
chronic HCV-infection will likely rise.
Nearly twenty years of experience with HIV treatment has led
to a sophisticated understanding of the ‘‘cascade of care’’ that
occurs between diagnosis and achieving durable HIV virologic
suppression [2]. There is a similar cascade for HCV, which
requires linking to HCV care, receiving confirmatory testing,
staging disease, initiating therapy, and adhering to therapy despite
adverse effects [3]. Compared to HIV, there are significant
differences in benefits and costs of addressing the HCV cascade,
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e97317because unlike HIV, effective HCV treatment results in a cure
(sustained virologic response, SVR) [4,5].
In the era of pegylated interferon and ribavirin-based HCV
therapy, only 7–10% of those with identified HCV infection ever
attained SVR [6–10]. As screening expands and treatments
improve, there is growing interest in developing interventions to
improve follow-up with HCV care after diagnosis [11]. Such
interventions may target a single or multiple points along the HCV
cascade of care, but there are no data to suggest which types of
interventions along the cascade are likely to have the greatest
impact on clinical or cost-effectiveness outcomes. For example,
would limited resources be best employed to improve linkage to
HCV care, or to improve the percentage of those already linked to
care that initiates HCV therapy? Further, are resources best used
to maximize follow-up at one point in the cascade where follow-up
is particularly poor, or should we target multiple points
simultaneously even if an intervention with multiple targets is
somewhat less effective than a more narrowly targeted interven-
tion at improving follow-up at any individual point?
Mathematical modeling provides a useful approach for com-
paring intervention strategies prior to intervention implementation
and affords decision-makers with reasonable estimates as to
whether the interventions, if effective, are likely to be the most
efficient use of limited resources. Once priority strategies are
identified through mathematical modeling, comparative effective-
ness trials can be designed to test the efficacy of specific
interventions, and implementation science can identify and
address barriers to implementation [12].
We used the Hepatitis C Virus Cost Effectiveness (HEP-CE)
model, a mathematical model of HCV disease progression and
care delivery, to estimate the impact of loss to follow-up along the
cascade of HCV care on clinical outcomes and costs, and to
identify specific interventions that are promising candidates for
future intervention design, evaluation, and implementation
research. Each hypothetical intervention targeted one or more
distinct points along the cascade of care, with different cost and
implementation assumptions in order to identify the most effective
and cost-effective strategies.
Methods
Overview
We used the Hepatitis C Cost-Effectiveness (HEP-CE) model, a
Monte Carlo simulation of HCV natural history and care delivery,
to simulate the progression of a cohort of HCV mono-infected
individuals recently identified with HCV antibody (Ab) sero-
reactivity. Details of the model are published elsewhere [13,14]
and are presented in Appendix S1. We sought to answer 3
questions:
1. How does loss to follow-up along the cascade of HCV care
affect the clinical benefits of current and future therapies?
2. Which approaches to reducing loss to follow-up are likely to
provide the best value for the resources invested and should
therefore be prioritized for future development?
3. What are the likely program budgetary impacts and clinical
outcomes of the simulated interventions?
Clinical outcomes included life expectancy and discounted
quality-adjusted life expectancy (QALE). Process outcomes
included the proportion of individuals linking to HCV care,
initiating HCV therapy, and attaining SVR. The model also
generated two cost estimates:
1. Mean discounted lifetime medical costs from a health system
perspective - the costs of hospitalizations, emergency depart-
ment visits, and outpatient visits, as well as the costs of
interventions, and those of HCV treatment for the portion of
patients who initiate HCV therapy. These health system
perspective medical costs are discounted at 3% annually over a
lifetime time horizon [15].
2. Program costs from the perspective of a program director
implementing retention interventions – the costs of the
intervention itself, undiscounted, over a 5-year time horizon.
Model Structure
Cascade of care. The simulated cohort includes chronically
HCV-infected individuals who have been recently screened
positive for HCV-infection. After screening, individuals enter a
cascade of care in which they face a probability of completing each
successive step, conditional upon having successfully navigated the
previous step (Figure 1, Figure S1 in Appendix S1). We used
estimates from published observational cohorts to inform the
following parameter values:
1. Obtaining HCV screening results (74%) [16–18]
2. Linking to HCV care (53%) [16,19–22]
3. Receiving diagnostic test results (98%) [7,23]
4. Deciding on and initiating HCV therapy (27%) [8,24,25]
5. Adhering to and completing HCV therapy (83%–91%) [26–
29]
When individuals fail to navigate a step in the cascade, they are
considered lost to follow-up. Consistent with published data from
observational cohorts, when patients are not engaged with HCV
treatment their HCV disease progresses, they continue to
experience decreased quality-of-life that is a function of their
degree of fibrosis, and they continue to accrue health care costs
related to their HCV-infection [14,30–38]. Simulated individuals
lost to follow-up maintain a probability of ‘‘re-linking’’ to care over
the following 10 years as a result of re-testing or further
engagement with the health care system.
HCV disease progression. Individuals with chronic HCV-
infection progress in the model through 3 stages of liver disease:
mild to moderate fibrosis, cirrhosis, and decompensated cirrhosis
[39]. When histology reaches cirrhosis (median time 25 years from
age of infection), individuals face a probability of mortality
attributable to liver disease, from either complications due to
cirrhosis or hepatocellular carcinoma [40–42]. Individuals develop
cirrhosis at different rates. For example, some individuals begin
the simulation with cirrhosis, while others never develop cirrhosis
despite their HCV-infection. At all disease stages, HCV-infection
is associated with increased health care costs and decreases in
quality-of-life that were varied in sensitivity analyses [30–38].
Individuals who attain SVR are exposed to a risk of HCV re-
infection [43]. Those who are re-infected may be re-treated, but
only if they are screened for HCV and again navigate the HCV
cascade of care. We assume that individuals who attain SVR are
exposed to re-infection risk throughout the rest of their life, as on-
going or relapsed injection drug use has been cited as a factor
limiting the effectiveness of interventions to improve HCV
treatment rates [44]. Such an assumption is conservative from
the perspective of evaluating intervention efficacy, by reducing the
impact of effective interventions. When re-infected, individuals
resume HCV disease progression at the stage of fibrosis that they
had reached during their prior HCV-infection.
HCV Treatment Cascade of Care
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genotype and fibrosis stage [26,28,29]. The base case HCV
therapy regimens reflect the standard of care at the time that we
completed the analysis. Individuals with genotype 1 infection
receive 24–48 weeks of pegylated interferon (PEG), ribavirin
(RBV), and telaprevir (TPV) combination therapy including early
stopping criteria for treatment futility [45]. We chose TPV (rather
than boceprevir) for the base case due to its straightforward
treatment algorithm and because its higher upfront costs result in
more conservative estimates of the cost-effectiveness of treatment
[46]. In sensitivity analyses, we included a scenario that included
the lower up-front cost of boceprevir. For those with genotypes 2
or 3 infection, we modeled PEG/RBV therapy [28,29].
For all genotypes and regimens, in each month patients face a
probability of withdrawal from therapy due to either treatment
toxicity or non-adherence. Patients who withdraw from therapy
due to toxicity accrue additional costs (Table S1 in Appendix S1).
Patients who withdraw prior to the end of their intended treatment
course stop accruing the costs of therapy and are not eligible to
attain SVR; we did not include re-treatment in this analysis for
those that fail.
Because HCV therapy is rapidly evolving, we also simulated a
scenario in which individuals chronically infected with all HCV
genotypes were treated with an oral, interferon-free regimen that
avoids common toxicities associated with interferon [47,48].
Because we anticipate that any specific interferon-free regimen
could be replaced quickly by an even newer generation of therapy,
we opted to simulate a hypothetical interferon-free option, rather
than ‘‘over fit’’ the model to a specific treatment course. To that
end, we modeled a 12-week course of oral interferon-free therapy
for all HCV genotypes, without criteria for stopping therapy early
for treatment futility. We used reports from phase 2 and 3 clinical
Figure 1. Cascade of care flow diagram. The flow diagram represents the steps of the HCV cascade of care, as well as key model parameters
related to loss to follow-up. Arrows noted in the key represent points along the cascade at which candidate interventions improved follow-up.
Individuals lost to follow-up prior to receiving their screening test results maintained a rate of re-screening such that their HCV status could be
identified in the future (median time to first re-screen=50 months). In addition, those who were lost to follow-up after obtaining screening test
results had a monthly probability of re-linking to HCV care (median time to re-link=32 months).
doi:10.1371/journal.pone.0097317.g001
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inform treatment efficacy [48–51]. We used the cost of a 12-week
course of sofosbuvir and ribavirin as the cost of interferon-free
therapy, and we varied this assumption widely in sensitivity
analyses. We also assumed that individuals would be more likely to
initiate interferon-free therapy compared to PEG/RBV regimens
(54% vs 27%) and less likely to drop out of therapy because of
reduced toxicity and improved convenience (Table 1).
Treatment costs include those of medications, provider visits,
laboratory monitoring, and management of common toxicities
(Table 1, Table S2 in Appendix S1) [46,52–55]. Consistent with
findings from large cohort studies, successful HCV therapy results
in cessation of HCV-related disease progression, reduction in liver-
related mortality and health care resource utilization, and return
of quality-of-life to that of age-matched HCV-uninfected individ-
uals [4,56–58].
Analyses
Cohort. The simulated cohort was comprised of one million
chronically HCV-infected individuals whose demographic and
clinical composition matched those of HCV-infected individuals in
the U.S. [59]. The mean age was 55 (standard deviation 10) years
and the cohort was 63% male [59]. Reflecting the cohort age,
early age at infection (26 years), and median time to developing
cirrhosis (25 years from age of infection), 46% of the cohort had
cirrhosis at simulation baseline (Table 1) [41,60]. We excluded
individuals co-infected with HIV because these individuals have
different opportunities for cascade of care interventions and
different HCV treatment outcomes.
Impact of imperfect follow-up on clinical outcomes. We
used the model to simulate the cohort under 2 scenarios. First, we
assumed status quo rates of loss to follow-up along each point in
the cascade of care. Second, we assumed an optimal scenario in
which medical contraindications to interferon and medication-
related toxicity continued to limit HCV treatment initiation and
completion, but in which follow-up along the cascade was perfect
and, in patients who did not have drug-related toxicity, adherence
to therapy was perfect. In the optimal follow-up scenario, 100% of
those identified as HCV-infected linked to care, those without a
medical contraindication initiated therapy (55%), and the only
reason for withdrawal from HCV therapy was medication-related
toxicity [8,24,25,61]. We attributed the difference in outcomes
between the 2 scenarios to the loss to follow-up along the cascade.
Simulated interventions to improve follow-up. We mod-
eled 4 hypothetical interventions to improve HCV outcomes:
1) Linkage intervention - a 3-month intervention based on the
Anti-Retroviral Treatment and Access to Services (ARTAS)
case management program, which includes up to 5 visits with
a case manager and is designed to improve linkage to care
rates, at a cost of $1,900/patient [62,63].
2) Treatment initiation intervention - a 3-month intervention
targeting individuals already engaged in HCV care to
enhance the probability of initiating treatment prior to
treatment start. We used expert opinion to describe a
hypothetical intervention that includes an extended visit with
a physician, 2 nursing visits, and supportive services from a
case manager (such as assistance with insurance forms,
obtaining public benefits, and coordinating appointments) at
a cost of $1,000/patient.
3) Integrated case management (ICM) intervention - a 6-month
intervention that uses case managers to improve both linkage
to HCV care as well as the probability of initiating treatment
at a cost of $2,200/patient. ICM combines the components of
both the linkage and treatment initiation interventions and is
designed to occur before treatment start.
4) Peer navigator intervention – a 12–18-month intervention
that uses peer navigators to work with clients from the time
they are diagnosed as HCV-infected through the completion
of HCV treatment. We modeled the peer navigator
intervention on the New York City Department of Public
Health and Mental Hygiene’s ‘‘Check Hep C’’ program [11].
The intervention encompasses the 3–6 month period patients
spend in HCV care prior to starting therapy through the 6–12
months (depending on HCV genotype and response to
treatment) patients spend on HCV treatment at a cost of
$5,300/patient.
Intervention effectiveness. The interventions affected one
or more point(s) along the HCV cascade of care (Figure 1). We
modeled the effectiveness of the linkage intervention by increasing
the probability that an individual with chronic HCV-infection
with recently identified reactive HCV serum Ab would present to
HCV care for evaluation. For the treatment initiation interven-
tion, we increased the proportion initiating HCV treatment after
linking to care. For the ICM intervention, we increased both the
probability of linking to HCV care and the probability of initiating
HCV therapy. Finally, we modeled the peer navigator interven-
tion by increasing the probability of linking to HCV care and
initiating treatment, and decreasing the rate of withdrawal from
HCV therapy due to non-adherence.
We used expert opinion to develop a base case effect size for a
successful intervention strategy. We assumed that effective
interventions would increase follow-up at each targeted point(s)
along the cascade of care by 10 absolute percentage points. We
varied this assumption in sensitivity analyses from 2 to 40
percentage point absolute increases in the effectiveness of the
interventions at each of their targeted points in the cascade. In
further sensitivity analyses we altered the approach to model a
10% relative improvement in follow-up at the relevant points along
the cascade. Additionally, we conducted analyses in which we
assumed that interventions that simultaneously target multiple
points along the cascade have less impact at any single point
compared to interventions that target a single point.
The interferon-free treatment scenario included several key
changes to both the standard of care and interventions strategies
including:
1. Higher probability that individuals would initiate HCV
therapy in the absence of an intervention, reflecting the
improved tolerability of an IFN-free regimen.
2. Lower cost for the peer navigators, reflecting the shorter
treatment duration using IFN-free therapy.
3. Lower probability of non-adherence in the absence of a peer
navigator, reflecting the elimination of weekly interferon
injections and a lower toxicity profile.
Program costs. Program costs included labor, materials, and
overhead related to administering a hypothetical intervention. We
used public health literature, U.S. Bureau of Labor Statistics data
and Medicare reimbursement schedules to identify the materials
and human resource costs needed to implement the hypothetical
interventions (Table 1, Table S3 and Table S4 in Appendix S1)
[11,62–66].
The model applies program costs on a monthly basis only
during months in which an individual receives care; if an
individual is lost to follow-up before completing an intervention,
the subsequent monthly program costs are not incurred. The
HCV Treatment Cascade of Care
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Variable Base Case Value Range Evaluated Source
Cohort characteristics
Mean age, years (S.D.) 55 (10) 45 (10) –65 (10) [59]
Proportion male 0.63 0.40–0.80 [59]
Proportion with genotype 1 0.73 0.60–0.90 [75–78]
Average age at infection (years) 26 16–36 [60]
Cascade of care variables
Proportion receiving screening test results 0.74 0.18–0.84 [16–18]
Proportion linking to HCV care
a 0.53 0.45–0.93 [16,19–22], See text
Proportion receiving diagnostic test results 0.98 0.95–1 [7,23]
Proportion initiating HCV therapy
b 0.27 0.19–0.67 [8,24,25], See text
10 year probability of re-engaging with care after being lost to follow-up 0.27 0–0.53 See text
HCV disease progression
Median time from infection to cirrhosis (years) 25 10–40 [41,42]
Median time from cirrhosis to first decompensation (years) 10.8 5.6–19.3 [40,79]
Liver-related mortality with cirrhosis (deaths/100 PYs) 2.73 1.38–4.08 [80]
Incidence (infections/100 PYs) 0.66 0–1.32 [59]
Probability of clearing acute infection 0.26 0.22–0.29 [81,82]
HCV therapy efficacy
Genotype 1 (PEG/RBV/TPV) [26,27]
Probability of withdrawal due to non-adherence 0.06 0.01–0.09
Probability of withdrawal due to toxicity 0.11 0.01–0.16
Probability of SVR for non-cirrhotics 0.75 0.60–0.95
Probability of SVR for cirrhotics 0.63 0.60–0.95
Genotype 2 or 3 (PEG/RBV) [28,29]
Probability of withdrawal due to non-adherence 0.06 0.01–0.10
Probability of withdrawal due to toxicity 0.03 0.01–0.06
Probability of SVR for non-cirrhotics 0.74 0.55–0.95
Probability of SVR for cirrhotics 0.58 0.55–0.95
Interferon-free regimen [48–51].
Probability of withdrawal due to non-adherence 0.02 0–0.04
Probability of withdrawal due to toxicity 0.006 0–0.010
Probability of SVR for non-cirrhotics 0.90 0.80–1
Probability of SVR for cirrhotics 0.81 0.70–0.90
Costs
Routine medical costs per month without HCV
c $140–$920 $70–$1,380 [83]
Routine medical costs per month with HCV
c $250–$1,500 $125–$2,250 [83,84]
Diagnostic testing once screened positive
d $80 $40–$120 [54,55]
Program costs per participant
e
Linkage intervention $1,883 $905–$4,518 [62]
Treatment initiation intervention $1,021 $1,021–$4,475 [62], See text
ICM intervention $2,191 $1,470–$6,716 [62], See text
Peer navigator intervention $5,344 $1,243–$5,344 [11,62]
HCV therapy costs per month
Provider visit costs
f $121 $61–$182 [54,55]
PEG
g $1,572–$2,097 $786–$3,146 [46]
RBV
h $685–$1,371 $343–$2,057 [46]
TPV
i $15,154 $7,577–$22,731 [46]
Filgrastim
j $1,900 $950–$2,850 [46]
HCV Treatment Cascade of Care
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five-year time horizon. To estimate lower and higher cost
scenarios for each intervention, we varied the average caseload
that intervention staff members could carry.
Incremental cost-effectiveness. We calculated the incre-
mental cost-effectiveness ratio (ICERs) of an intervention com-
pared to the next best alternative as the additional cost divided by
the QALY gain ($/QALY) [67,68]. Interventions that had higher
costs but fewer QALYs gained, as well as those that had a higher
cost per QALY than a more effective intervention were considered
‘‘dominated’’ and no ICER was calculated. All costs are in 2011
U.S. dollars. QALYs and costs for ICERs were discounted at 3%
annually [68]. For purposes of interpreting cost-effectiveness
analyses, we assumed a U.S. societal willingness to pay threshold
of $100,000/QALY gained [69,70].
Results
Outcomes of Imperfect Follow-up
When we assumed the current standard of care (SOC), we
estimated that 15% ever initiated HCV treatment, and 10%
ultimately attained SVR (Figure 2). When we assumed ideal
follow-up along the cascade of care, we estimated that 56% ever
initiated HCV treatment and 41% attained SVR. Thus, due to
loss to follow-up, we estimate that the proportion achieving SVR
was approximately 25% of the theoretical best-case scenario.
Interventions to Improve Follow-up
Simulating a hypothetical intervention that improved linkage to
care from 53% to 63% resulted in a 14% increase in the number
attaining SVR compared to the current SOC (Figure 2). Mean life
expectancy increased from 21.30 to 21.36 years, QALE from 9.99
to 10.06 QALYs, and discounted lifetime medical costs from
$189,000 to $190,700 (Table 2).
When we simulated a similarly effective intervention that
improved treatment initiation from 27% to 37%, we observed an
18% increase in the number attaining SVR compared to the
linkage intervention and an estimated 36% increase compared to
SOC. Life expectancy was 21.50 years, greater than that of both
the SOC and the linkage intervention scenarios. QALE was 10.21
QALYs, and discounted lifetime medical costs were $193,100.
When considering only the 2 hypothetical interventions that
intervened at a single point along the cascade, the more distally
targeted intervention along the cascade (treatment initiation)
dominated the more proximally targeted intervention (linkage),
meaning that it provided longer life expectancy than linkage at a
lower cost per QALY gained.
Table 1. Cont.
Variable Base Case Value Range Evaluated Source
Clobetasol propionate
k $160 $80–$240 [46]
Complete course genotype 1
l $67,530–$89,742 $44,871–$134,613 [46,55]
Complete course genotype 2/3 $22,627 $11,314–$33,941 [46,55]
Complete course of IFN-free (all genotypes) $91,500 $80,000–$200,000 See text
Managing treatment ending toxicity $361 $181–$542 [46,52,53,55]
Quality of life
Without HCV infection
m 0.90 0.80–1.0 [85–87]
HCV with no to moderate fibrosis 0.89 0.75–1.0 [32,34,37]
HCV with cirrhosis 0.62 0.55–0.75 [32,34,37]
HCV after first decompensation event 0.48 0.40–0.60 [32,34,37]
On HCV treatment
n 0.90 0.84–0.96 [88]
Major toxicity decrement
o 0.16 0.09–0.25 [89]
S.D.=standard deviation; PY=person-year; PEG=pegylated interferon; RBV=ribavirin; TPV=telaprevir; SVR=sustained virologic response; ICM=integrated case
management; IFN=interferon.
aThe lifetime probability of linking to HCV care upon receipt of a positive antibody result is 66%.
bIn the interferon-free scenario, we assumed that 54% of those linked to care would initiate therapy.
cCosts varied as a function of age and sex.
dIncludes the cost of a RNA confirmatory test and a nursing visit.
entervention costs are presented on a per participant basis, assuming that the participant completes the entire intervention. During the simulation, participants accrued
costs on a monthly basis. If the participant was lost to follow-up, or otherwise withdrew from care before the end of the intervention, then that patient stopped
accruing intervention costs at the time of being lost (see Appendix S1 for details).
fTreatment visit costs are higher in the first month compared to other months.
g13% of patients received a reduced weekly dose of 135 mcg in response to non-treatment ending neutropenia [45].
hRBV dose was a function of genotype (genotype 1=1,200 mg/day; genotype 2 or 3=800 mg/day). In addition, 36% of patients on triple therapy and 17% on dual
therapy were treated with reduced dose RBV=600 mg/day in response to non-treatment ending anemia [45].
iOnly patients with genotype 1 receive TPV for treatment months 1–3.
j13% of patients developed non-treatment ending neutropenia (absolute neutrophil count ,750/ml) and received filgrastim 300 mcg/two times weekly [45].
kOnly patients with genotype 1 treated with PEG/RBV/TPV therapy received 150g/month for treating mild rash (28% during the first 3 months of therapy) [45].
lThe range reflects the fact that some patients were treated for 6 months, while those without rapid virologic response were treated for 12 months.
mReflects lower quality of life for individuals with HCV risk-factors such as substance use.
nThis utility weight was multiplied by an individual’s health state utility during the months that a patient was receiving HCV therapy without major toxicity. For example,
a patient with HCV and mild to moderate fibrosis who underwent HCV treatment had a utility=0.801 (0.9060.89) during the months that (s)he was on medications.
oThis utility ‘‘toll’’ was subtracted from a patient’s health state utility during the month of a major toxicity event.
doi:10.1371/journal.pone.0097317.t001
HCV Treatment Cascade of Care
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treatment initiation by 10 percentage points resulted in the same
number of patients linking to care as the linkage intervention, but
it resulted in more patients initiating therapy and attaining SVR
than either the linkage or treatment initiation interventions alone.
As a result, we found that the ICM intervention dominated both
linkage and treatment initiation interventions with an ICER
compared to SOC of $19,100/QALY gained (Table 2).
Finally, we estimated that implementing a hypothetical com-
prehensive peer navigator program would provide a 1.0% increase
in the proportion of patients achieving SVR compared to the ICM
program. We found that the hypothetical peer program extended
life expectancy, QALE, and costs compared to ICM with an ICER
of $48,700/QALY gained.
Program Costs
For a cohort of 10,000 hypothetical HCV-infected individuals,
the undiscounted 5-year cost of implementing each simulated
intervention was $6.4 million for linkage, $7.6 million for
treatment initiation, $11.5 million for ICM, and $14.5 million
for peer navigators.
Sensitivity Analyses on Intervention Effectiveness and
Costs
The projected ICERs for the simulated ICM and peer navigator
interventions remained ,$100,000/QALY across broad assump-
tions about intervention effectiveness (Figure 3). The ICER of
ICM remained ,$50,000/QALY gained, even when we assumed
that all interventions improved follow-up by only 2 percentage
Figure 2. Intervention clinical outcomes. The bar graph illustrates the percent of the cohort attaining clinical outcomes along the HCV cascade
of care. Each bar shading represents a specific intervention scenario.
doi:10.1371/journal.pone.0097317.g002
Table 2. Projected incremental cost effectiveness ratios of potential interventions to improve HCV follow-up.
Strategy Undiscounted Discounted Incremental ICER ($/QALY)
Life Expectancy Cost ($) QALY Cost ($) QALY
Standard of Care 21.30 189,000 9.99 – – –
Linkage 21.36 190,700 10.06 1,700 0.07 dominated
a
Treatment Initiation 21.50 193,100 10.21 2,400 0.15 dominated
b
Integrated Case Management 21.59 194,800 10.30 1,700 0.09 18,900
Peer Navigator 21.60 195,300 10.31 500 0.01 48,700
c
QALY=Quality-adjusted life year; ICER=incremental cost-effectiveness ratio.
Costs and QALYs are lifetime and discounted at an annual rate of 3%. Costs are in 2011 U.S.$ and rounded to the nearest $100. All QALYs are rounded to the nearest
hundredth.
aThe ICER of linkage compared to standard of care is $26,500/QALY gained; linkage is extended dominated.
bThe ICER of treatment initiation compared to standard of care is $19,200/QALY gained; treatment initiation is extended dominated.
cThe ICER of peer navigators compared to standard of care is $20,000/QALY gained.
doi:10.1371/journal.pone.0097317.t002
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relative to ICM remained ,$100,000/QALY gained unless all
interventions improved follow-up by fewer than 4 percentage
points.
The ICER of peer navigators compared to ICM was sensitive to
the effectiveness of the peers. With any assumption of decreased
retention relative to ICM, peer navigators no longer had an ICER
,$100,000/QALY gained, even when we assumed that the labor
cost of the peers was lower than that of case managers.
When we reduced the effectiveness of both the simulated peer
navigator and ICM interventions compared to interventions that
solely targeted linkage or treatment initiation, peer navigators
continued to be more effective and provided the best value for
money. We estimated that only when the outcomes of peer
navigators and ICM were less than 80% of the treatment initiation
intervention did the treatment initiation intervention become
preferred.
When we modeled intervention effectiveness as a 10% relative
improvement (rather than a 10 percentage point absolute
improvement) compared to SOC, results were similar. Again,
when considering only single point interventions, the more distally
targeted intervention along the cascade of care (treatment
initiation) dominated the proximally targeted intervention (link-
age). Both single point interventions, however, were economically
inefficient compared to hypothetical interventions that targeted
multiple points along the cascade (ICM and peer navigators). Peer
navigators remained the preferred strategy with an ICER of
$35,900/QALY gained compared to ICM.
When we increased the cost of ICM, the ICER of ICM
compared to its next best alternative remained ,$100,000/QALY
gained as long as the estimated cost of ICM was less than $2,900
per participant (base case $2,191). We found that at higher costs,
ICM was no longer efficient as peer navigators provided a greater
life expectancy benefit at lower cost per QALY gained. Likewise,
the ICER of the peer navigators was less than $100,000/QALY as
long as the cost of the intervention was less than an estimated
$6,700 per participant (base case $5,344).
Sensitivity Analyses Assuming Interferon-free Therapy
With the availability of interferon-free therapy, assuming the
same linkage rates, but an improvement in treatment initiation
and adherence to therapy compared to current therapy, we
estimated that 27% of individuals attained SVR. Life expectancy
increased from 21.30 to 22.08 undiscounted life years, and QALE
increased from 9.99 to 10.87 QALYs. With interferon-free
treatment, peer navigators dominated all other interventions by
providing additional SVR benefits at a lower cost per QALY
gained with an ICER of $16,200/QALY gained compared to
SOC. Life expectancy with peer navigators was 22.49 years,
QALE was 11.32 QALY, and discounted, lifetime medical costs
were $207,300. When we assumed that adherence to IFN-free
therapy would be lower in the real-world than it was in clinical
trials, peer navigators continued to dominate all other interven-
tions.
Additional Sensitivity Analyses
When we varied other model parameters including cohort
characteristics, HCV disease progression, HCV therapy efficacy,
costs and quality-of-life, all of the simulated interventions had
ICERs ,$100,000/QALY gained compared to the SOC, and
linkage and treatment initiation interventions were consistently
dominated by either ICM or peer navigators. When we assumed a
longer median time from infection to the development of cirrhosis
(40 years), which corresponded to a lower prevalence of cirrhosis
at simulation baseline (18%), ICM and peer navigators continued
to dominate linkage and treatment initiation interventions, and the
ICER of peers compared to ICM was $51,200/QALY. All
hypothetical interventions became more economically attractive
(lower ICERs) when we assumed greater treatment efficacy and
increased HCV-attributable morbidity and mortality. When we
assumed less withdrawal from therapy due to non-adherence, the
ICER of peer navigators compared to ICM increased substan-
tially, and ICM was the preferred intervention. Assumptions about
the costs of HCV medications and management of HCV
treatment had little impact on findings.
Discussion
Using mathematical modeling, this analysis estimates that loss to
follow-up along the cascade of HCV care reduces the effectiveness
of current HCV therapy by approximately 75%. We found that
without improvement in loss to follow-up along the HCV cascade
of care, the proportion of chronically HCV-infected individuals
who achieve SVR will likely not change substantially from
approximately 10%. More tolerable and effective interferon-free
therapy will likely improve outcomes, but even assuming improved
efficacy and a doubling in the proportion of patients initiating
HCV treatment, we project that only 23% of individuals identified
with chronic HCV-infection would be cured.
Investments in interventions to improve linkage to care,
treatment initiation, and adherence to HCV therapy are needed.
Our findings suggest that these potential interventions are likely to
have attractive cost-effectiveness ratios when compared to the
current SOC. Our work also demonstrates that interventions
addressing multiple points along the cascade, including distally
targeted points such as treatment initiation and therapy adher-
ence, will likely provide better outcomes at more attractive ICERs
than those targeting either a single point, or targeting points at the
proximal end of that cascade, such as linkage.
There are two reasons that comprehensive interventions may be
preferred to a targeted approach: first, interventions that address
distally targeted points in the cascade have a greater impact on
clinical outcomes than those that address loss to follow-up at
earlier phases. The finding that distally targeted points in the
cascade are critical is not unique to HCV-infection, as similar
Figure 3. Incremental cost-effectiveness ratios (ICERs) of
increased intervention effectiveness. The line graph illustrates
the incremental cost-effective ratio (ICER) of the peer navigator and
integrated case management hypothetical interventions compared to
the next best alternative across a range of intervention effectiveness.
doi:10.1371/journal.pone.0097317.g003
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and HIV [71,72]. Second, because the number of people who
reach the end of the cascade of HCV care is a multiplicative
function of the probability of loss to follow-up at every point along
the cascade, interventions that improve follow-up at multiple
points create a synergy of effects that may justify the greater
resources required. For example, we found that a hypothetical
peer navigator intervention was preferred to a hypothetical
treatment initiation intervention unless the cost was over six times
that of a treatment initiation intervention. Additionally, based on
our assumptions, comprehensive interventions are more effective
than targeted interventions even when their impact at any single
step in the cascade of care is reduced by one fifth compared to an
intervention that devotes all of its resources to improvement at a
single step. Our results suggest that future studies should prioritize
the development and evaluation of comprehensive interventions
such as peer navigators or integrated case management, as these
interventions are likely to provide not only better outcomes than
linkage or treatment initiation interventions, but also better value
for the resources invested.
There are limitations to this analysis. First, this is a simulation
modeling analysis that relies on projections of the effectiveness and
costs of hypothetical interventions. The simulation approach,
however, provides guidance needed to inform and prioritize
potential efforts to improve HCV care. The goal of this analysis is
not to report the cost-effectiveness of a real-world program.
Rather, we seek to simulate outcomes with hypothetical interven-
tions in order to develop priorities for prospective, hypothesis-
driven evaluation. We carefully considered all of the components
of interventions, including overhead and administrative costs,
using existing HIV and HCV interventions as models. In
sensitivity analyses, we considered a variety of scenarios varying
effectiveness and cost. The finding that comprehensive approaches
are more economically attractive than single-point interventions
was consistent across the range of reasonable assumptions.
Additionally, while we considered a variety of strategies to
increase the number of people navigating the HCV cascade of
care, we did not model alternative approaches to HCV treatment
itself. For example, we did not model strategies that use IL28B
genotyping to prioritize patients for protease-based therapy.
Previous work indicates that such an approach may be cost-
effective [73,74]. Our goal in this analysis, however, was to focus
on the cascade of care itself, not to investigate the cost-effectiveness
of the accepted standard of HCV therapy. Were we to model both
interventions to improve follow-up along the cascade, and novel
treatment strategies, the relative contributions of multiple simul-
taneous interventions would be difficult to interpret. Any
treatment algorithm that improves the value of HCV therapy in
terms of cost per QALY gained, however, will also improve the
value of interventions that increase the number of people starting
therapy. As a result, novel approaches that improve the economic
value of HCV therapy will likely improve the cost-effectiveness of
cascade of care interventions and our results remain conservative.
Third, we included costs from a health system perspective, and
therefore did not include patient time in the analysis. Relative to
HCV treatment and intervention costs, patient time is a small
percentage of total cascade of care costs. We varied intervention
costs widely, and these sensitivity analyses may be interpreted as
scenarios with and without patient time costs.
Finally, the base case analysis assumes HCV treatment using an
HCV protease inhibitor in combination with interferon, which will
not be the standard of care in the future. Given the rapid pace of
HCV drug discovery, a modeling approach is advantageous as it
projects costs and effectiveness under a variety of assumptions
about future treatment. We considered a scenario utilizing more
effective and less toxic interferon-free therapy based on available
data, and we projected that comprehensive interventions such as
peer navigators are more economically attractive as therapy
becomes more costly and effective, even at our assumed increased
cost of interferon-free therapy.
In conclusion, this analysis demonstrates that although nearly
any effective intervention to improve follow-up in the HCV
cascade of care will likely improve HCV outcomes, comprehensive
approaches that focus on multiple points along the HCV cascade,
such as peer navigators or integrated case management, may
provide the best value for money and should be prioritized for
future development and prospective evaluation.
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